A 20 meta-analysis review looking at ACE inhibitors demonstrated a reduction in cardiovascular events but also slowed the decline of renal failure by 39% when compared to placebo. An analysis on the PROGRESS trial showed that perindopril has key benefits in reducing cardiovascular events by 30% in patients with chronic kidney disease defined as a CrCl Assess kidney function before and during treatment where appropriate.Situations where a patient has a history of hypersensitivity.The combination of amlodipine and perindopril remains in the current treatment guidelines for hypertension and the outcomes of the ASCOT-BLA trial paved the way for further research into combination therapy and newer agents. The study of more than 19 000 patients world-wide was terminated earlier than anticipated because it clearly demonstrated a statistically significant improvement in mortality and cardiovascular outcomes with the newer treatment. The Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm ( ASCOT-BLA) was a 2005 landmark trial that compared the effects of the established therapy of the combination of atenolol and bendroflumethiazide to the new drug combination of amlodipine and perindopril (trade names Viacoram, Acer圜al etc.). There is evidence to support the use of perindopril and indapamide combination over perindopril monotherapy to prevent strokes and improve mortality in patients with a history of stroke, transient ischaemic attack or other cardiovascular disease. In addition, the Perindopril pROtection aGainst REcurrent Stroke Study ( PROGRESS) found that whilst perindopril monotherapy demonstrated no significant benefit in reducing recurrent strokes when compared to placebo, the addition of low dose indapamide to perindopril therapy was associated with larger reductions in both blood pressure lowering and recurrent stroke risk in patients with pre-existing cerebrovascular disease, irrespective of their blood pressure. In combination with indapamide, perindopril has been shown to significantly reduce the progression of chronic kidney disease and renal complications in patients with type 2 diabetes. Perindopril shares the indications of ACE inhibitors as a class, including essential hypertension, stable coronary artery disease (reduction of risk of cardiac events in patients with a history of myocardial infarction and/or revascularization), treatment of symptomatic coronary artery disease or heart failure, and diabetic nephropathy. It is also often combined with another medication, sometimes in the same tablet (see #Combinations below). Both forms are therapeutically equivalent and interchangeable, but the dose prescribed to achieve the same effect differs between the two forms. Perindopril is taken in the form of perindopril arginine (trade names include Coversyl, Coversum) or perindopril erbumine ( Aceon). It was patented in 1980 and approved for medical use in 1988. As a prodrug, perindopril is hydrolyzed in the liver to its active metabolite, perindoprilat. Īs a long-acting ACE inhibitor, it works by relaxing blood vessels and decreasing blood volume. Perindopril is a medication used to treat high blood pressure, heart failure, or stable coronary artery disease.
0 Comments
Leave a Reply. |